Recurrence and death in non-small cell lung carcinomas: a prognostic model using pathological parameters, microvessel count, and gene protein products.

The 5-year survival rate of non-small cell lung carcinoma (NSCLC) has only marginally improved during the past two decades, despite advances in surgery and chemoradiotherapy. Major efforts are currently directed toward biological characterization of these tumors to define biomarkers able to add further prognostic information, thus improving new therapeutic protocols. We analyzed the predictive relevance of the microvessel count (MC), bcl-2 and p53 proteins, proliferative activity, and usual postsurgical parameters on recurrence and overall survival in a series of 70 patients with NSCLC. The expression of biological parameters (p53, bcl-2, proliferative activity, and MC) was detected using immunohistochemistry on paraffin-embedded and frozen sections from the tumors treated with surgical resection alone until relapse. In the univariate analysis, the histotype, tumor status, node status, p53, bcl-2, and MC have been shown to significantly affect progression and death. In the multiple logistic regression analysis, the MC (P < 0.000001), tumor status (P < 0.005), and node status (P < 0.0002) influenced the overall survival while prediction of relapse was strongly revealed by tumor status (P < 0.005), nodal metastatic involvement (P < 0.000001), and the assessment of the vascular count (P < 0.0004). These data have allowed the creation of a multivariate model which may add more information on risk of recurrence and death in patients with NSCLC and can form the basis for future randomized clinical trials.

[1]  A. Harris,et al.  Microvessel count predicts metastatic disease and survival in non‐small cell lung cancer , 1995, The Journal of pathology.

[2]  N. Weidner Intratumor microvessel density as a prognostic factor in cancer. , 1995, The American journal of pathology.

[3]  C. Angeletti,et al.  Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. , 1995, British Journal of Cancer.

[4]  H. Joensuu,et al.  Bcl-2 protein expression and long-term survival in breast cancer. , 1994, The American journal of pathology.

[5]  G. Niehans,et al.  Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma. , 1994, Journal of the National Cancer Institute.

[6]  S. Nasim,et al.  Prognostic significance of p53 overexpression in endometrial cancer. , 1994, Cancer research.

[7]  U. Veronesi,et al.  The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. , 1994, Journal of the National Cancer Institute.

[8]  A. Harris,et al.  Clinical prognostic significance of tumour angiogenesis. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  F. Rilke,et al.  Bcl‐2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland , 1994, The Journal of pathology.

[10]  H. Katz bcl-2 protein in non-small-cell lung carcinoma. , 1994, The New England journal of medicine.

[11]  A. Harris,et al.  bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. , 1994, British Journal of Cancer.

[12]  N. Weidner,et al.  Intratumoral microvessel density and L53 protein: Correlation with metastasis in head‐and‐neck squamous‐cell carcinoma , 1993, International journal of cancer.

[13]  A. Ghosh,et al.  Volunteer Duty , 1993, Environmental Health Perspectives.

[14]  D. Chopin,et al.  Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. , 1993, The American journal of pathology.

[15]  W Blumenfeld,et al.  Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. , 1993, The American journal of pathology.

[16]  G. Gibson,et al.  The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. , 1993, British Journal of Cancer.

[17]  U. Veronesi,et al.  p53 as an independent prognostic marker in lymph node-negative breast cancer patients. , 1993, Journal of the National Cancer Institute.

[18]  C. Angeletti,et al.  p53 expression in non small cell lung cancer: clinical and biological correlations. , 1993, Anticancer research.

[19]  W. McGuire,et al.  Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. , 1993, Journal of the National Cancer Institute.

[20]  A. Harris,et al.  Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer , 1992, The Lancet.

[21]  D. Quinlan,et al.  Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. , 1992, Cancer research.

[22]  C. Angeletti,et al.  Relation of neovascularisation to metastasis of non-small-cell lung cancer , 1992, The Lancet.

[23]  P. Meltzer,et al.  Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.

[24]  E. Kawasaki,et al.  Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. , 1992, Journal of the National Cancer Institute.

[25]  J. Monson,et al.  Is the relationship between angiogenesis and metastasis in breast cancer real? , 1992, Surgical oncology.

[26]  J. Folkman,et al.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.

[27]  S. Rodenhuis,et al.  K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. , 1990, The New England journal of medicine.

[28]  J. Folkman What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[29]  D. Hanahan,et al.  Induction of angiogenesis during the transition from hyperplasia to neoplasia , 1989, Nature.

[30]  R. Tsuchiya,et al.  Prognosis and survival in resected lung carcinoma based on the new international staging system. , 1988, The Journal of thoracic and cardiovascular surgery.

[31]  C. Mountain,et al.  A new international staging system for lung cancer. , 1987, Chest.

[32]  H Stein,et al.  Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). , 1984, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[33]  K. Chew,et al.  Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. , 1995, Journal of the National Cancer Institute.

[34]  J. Folkman Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. , 1995, The New England journal of medicine.

[35]  山崎 浩一 Tumor angiogenesis in human lung adenocarcinoma , 1995 .

[36]  G. Scagliotti,et al.  Prognostic significance of Ki67 labelling in resected non small cell lung cancer. , 1993, European journal of cancer.

[37]  M. Gerretsen,et al.  A phase III randomised trial of cisplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group. , 1990, British Journal of Cancer.

[38]  The World Health Organization. Histological typing of lung tumours. , 1982, Neoplasma.